VOYXACT Preserves Kidney Function for Two Years in Phase 3 IgA Nephropathy Trial
Otsuka Pharmaceutical’s VOYXACT (active ingredient: sibeprenlimab) demonstrated long-term kidney protection by maintaining kidney function over a...
Search results for "U.S. clinical trial"
As the U.S. Reconsiders Direct-to-Consumer Drug Ads, What Lessons Should We Learn?
During a yearlong stay in the United States, one of the things that struck me most was how easy it is to come across television and YouTube...
AI Platform Replaces Animal Models to Accelerate Parkinson’s Cell Therapy
Researchers are launching an international joint study that leverages artificial intelligence to evaluate whether...
Lilly’s Retatrutide Cuts Weight by 22.6% in Phase 3 Trials, But Cardiovascular Protection Remains Unproven
Eli Lilly and Company’s next-generation obesity treatment, retatrutide, reduced body weight by up to 22.
Celltrion Files for EU Approval of Cosentyx Biosimilar CT-P55, Targeting $6.7 Billion Autoimmune Market
Celltrion announced on the 24th that it has submitted a marketing authorization application to the European Medicines...
GSK Wins Early FDA Approval for Oral Lung Cancer Drug Jideytro Following $10.6 Billion Nuvalent Acquisition
A new oral therapy is now available for patients with ROS1-positive lung cancer whose disease has progressed following...
HLB Innovation Expands Phase 1 CAR-T Trial Following Clean Early Safety Data
HLB Innovation announced on July 23 that its U.S. subsidiary, Verismo Therapeutics, has expanded the Phase 1 clinical...
Novo Nordisk Secures EU Green Light for Oral Wegovy, Outpacing Eli Lilly in the Pill Market
The glucagon-like peptide-1 (GLP-1) obesity treatment market, long dominated by subcutaneous injections, is rapidly...
United Therapeutics Acquires Thymmune, Betting 460 Billion Won on Thymus Cell Therapy
The race to develop regenerative cell therapies for an ultra-rare disease that leaves patients born without a...
ABL Bio’s Stomach Cancer Drug Shows Promise in Once 'Untreatable' Patients
South Korean platform biotech company ABL Bio announced that development remains firmly on track despite investor...